Doctors test brain gene therapy to slow Parkinson's progression
NCT ID NCT01621581
Summary
This early-stage study tested the safety of a new gene therapy for people with advanced Parkinson's disease. Researchers delivered a gene (AAV2-GDNF) directly into the brain to help protect and strengthen the brain cells damaged by the disease. The main goal was to see if this experimental treatment was safe and tolerable for participants over a 5-year follow-up period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.